Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Terminated 2Unknown 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 9Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 7Glioblastoma 7Colorectal Neoplasms 6Gliosarcoma 5Neoplasm Metastasis 4Colonic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Rectal Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solitary Fibrous Tumor, Pleural 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Mesothelioma, Malignant 2Melanoma 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Astrocytoma 2Waldenstrom Macroglobulinemia 1

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × cediranib × Clear all
NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTINâ„¢) in Metastatic or Recurrent Renal Cell Carcinoma

AstraZeneca

Phase 2 Completed
105 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT00227760 2016-02-29

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
44 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell

NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡